Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for ...

Cash-strapped Viracta Therapeutics is continuing to reduce its options in order to stay afloat. Less than two months after ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever ...

Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...